Daten aus dem Cache geladen. Metastatic Melanoma Therapeutics: Advances in Treatment Options for...

Metastatic Melanoma Therapeutics: Advances in Treatment Options for Metastatic Melanoma

0
466

While ipilimumab was an important first approval, it only helped about 15-20% of patients and many experienced severe side effects. Since then, several other immunotherapies have been approved that have higher response rates and are generally better tolerated. Keytruda (pembrolizumab) was approved in 2014 for metastatic melanoma patients whose cancer had stopped responding to other treatments. It works by blocking PD-1, another protein that normally helps keep T cells in check. In clinical trials, around 40% of patients saw their tumors shrink or disappear completely in response to Keytruda.

Opdivo (nivolumab) was approved in 2014 as well. Like Keytruda, it also blocks PD-1 to help T cells better attack melanoma cells. Response rates were a bit lower than Keytruda initially at around 30%, but it was generally better tolerated with fewer side effects than ipilimumab. Both pembrolizumab and nivolumab have now been approved as earlier treatments for metastatic melanoma as well. Yervoy (ipilimumab) is still used, often in combination with nivolumab, since the dual immunotherapy approach can provide even higher response rates of around 57%.

Targeted Metastatic Melanoma Therapeutics

For
Metastatic Melanoma Therapeutics whose cancer no longer responds to immunotherapy, targeted therapies provide another treatment approach. These drugs target specific genetic mutations that drive melanoma growth and progression. BRAF inhibitors like vemurafenib (Zelboraf) were some of the first targeted therapies approved for metastatic melanoma. About 50% of melanomas have a mutation in the BRAF gene that makes the BRAF protein overactive. Vemurafenib targets and inhibits this mutated BRAF protein to stop tumor growth.

While initial response rates were high at around 48%, resistance often developed within 6-7 months. Combining a BRAF inhibitor with a MEK inhibitor to block downstream signaling helps prevent or delay resistance. Tafinlar (dabrafenib) combined with Mekinist (trametinib) was approved based on improved progression-free survival compared to vemurafenib alone. For patients with the BRAF V600 mutation, this combination provides a median progression-free survival of 9-11 months. Other targeted therapies in development aim to overcome resistance by inhibiting additional genes or pathways.

Combination Approaches Show Promise

Given their different mechanisms of action, combining immunotherapy with targeted therapy has become an active area of investigation. In a key study, treating melanoma with pembrolizumab plus the BRAF/MEK inhibitor combination led to response rates of 69% and median progression-free survival of 14.2 months. Another study found similar benefits from combining nivolumab with the BRAF/MEK inhibitors compared to BRAF/MEK therapy alone. Combining immunotherapies is also being explored, such as combining nivolumab and ipilimumab.

Get more insights on Metastatic Melanoma Therapeutics

Pesquisar
Categorias
Leia Mais
Jogos
Unlocking Dealing Likely: Some sort of Deeply Leap in Apex Trader Funding
  From the active earth connected with dealing, having access to investment capital can be...
Por Shahbaz Ansari 2024-10-12 08:15:31 0 174
Outro
Food Certification Industry Forecast: $9.48 Billion by 2032, 5.8% CAGR
Leading market research and consulting organization Polaris Market Research is excited to...
Por Ubaid Shaikh 2024-10-23 05:58:51 0 171
Jogos
Build Your Own High-ROI Swipe-to-Earn Game with Hivelance’s Notcoin Clone Script
Are you ready to enter the exciting world of Play-to-Earn (P2E) gaming?With Hivelance’s...
Por Peter Kester 2024-08-08 10:44:15 0 617
Causes
MB-700 Exam Dumps-Get Up-to-Date MB-700 Exam Questions
Are you planning to take the MB-700 exam but worry about failure? If yes then you ought...
Por Questions PDF 2022-11-03 06:01:32 0 2كيلو بايت
Outro
Hawaii Movers to Mainland: Seamless Relocation with JNR Global Logistics
Moving from Hawaii to the mainland can be a daunting task, but with JNR Global Logistics, it...
Por JNR Global 2024-11-21 07:49:32 0 171